Sudhir Paul

This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Igen, Inc., The Board of Regents of the University of Nebraska, Covalent Bioscience Incorporated. Active years: 1993-2024.

USPTO Granted Patents = 19 (Patent Applications = 3)

% Patents Active = 89.5

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.2

ph-index = 7

Forward Citations = 114(Granted Patents)

Location History:

Omaha, NE (US) (1993 - 2000)
Houston, TX (US) (2001 - 2005)
Missouri City, TX (US) (2005 - 2024)

Company Filing History:

The Board of Regents of the University of Nebraska

patents

2 out of 2

Covalent Bioscience Incorporated

patents

4. 1 out of 58

Igen International, Inc.

The University of Texas System

patents

7. 7 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2024

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071471 - Immunoglobulins directed to bacterial, viral and endogenous polypetides (2024-08-27),

2. 9969797 - Immunoglobulins directed to bacterial, viral and endogenous polypeptides (2018-05-15),

3. 9006388 - Covalent attachment of ligands to nucleophilic proteins guided by non-covalent (2015-04-14),

4. 8980646 - Proteolytic and covalent antibodies (2015-03-17),

5. 8246957 - Lupus antibodies for passive immunotherapy of HIV/AIDS (2012-08-21),

6. 7524663 - Covalently reactive transition state analogs and methods of use thereof (2009-04-28),

7. 6855804 - Covalently reactive transition state analogs and methods of use thereof (2005-02-15),

8. 6855528 - Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses (2005-02-15),

9. 6235714 - Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses (2001-05-22),

10. 6156541 - Compositions and methods for catalyzing hydrolysis of HIV gp120 (2000-12-05),

11. 6130049 - Assay methods and kits for diagnosing autoimmune disease (2000-10-10),

12. 6048717 - Inhibitors of catalytic antibodies (2000-04-11),

13. 5770570 - Method of delivering a vasoactive intestinal polypeptide, an (1998-06-23),

14. 5658753 - Catalytic antibody components (1997-08-19),

15. 5599538 - Autoantibodies which enhance the rate of a chemical reaction (1997-02-04),

Title: Sudhir Paul: Innovator in Biomedicine and Therapeutics

Introduction

Sudhir Paul is a distinguished inventor based in Omaha, NE, known for his significant contributions to the field of biomedicine. With an impressive portfolio of 19 patents, his work primarily focuses on the development of innovative immunoglobulins aimed at combating various diseases.

Latest Patents

Among Sudhir Paul's most recent patents are those related to immunoglobulins directed to bacterial, viral, and endogenous polypeptides. These patents disclose antibodies and fragments that have the ability to hydrolyze or bind polypeptide antigens associated with major health threats such as the hepatitis C virus, human immunodeficiency virus, and Alzheimer's disease. Additionally, he has introduced novel methods to enhance the antigen reactivity of these immunoglobulins, positioning them as promising therapeutics for treating pathophysiological conditions.

Career Highlights

Throughout his career, Sudhir Paul has not only been an innovator but also contributed to the growth of various organizations. His expertise has been instrumental in advancing research initiatives aimed at improving health outcomes through novel therapeutic approaches.

Collaborations

Sudhir has collaborated with notable professionals such as Yasuhiro Nishiyama and Michael Joseph Powell. These partnerships have facilitated the exchange of ideas and innovation, leading to groundbreaking advancements in the field of immunology and therapeutic development.

Conclusion

Sudhir Paul's work exemplifies the essence of innovation in medicine, showcasing how dedicated research and collaboration can lead to significant breakthroughs in health. His contributions continue to inspire upcoming inventors and researchers within the biomedicine landscape.